256 related articles for article (PubMed ID: 22594344)
1. Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes.
Nishida Y; Takahashi Y; Nakayama T; Asai S
Cardiovasc Diabetol; 2012 May; 11():53. PubMed ID: 22594344
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
3. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
4. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
5. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
6. Comparative Study of Metabolite Changes After Antihypertensive Therapy With Calcium Channel Blockers or Angiotensin Type 1 Receptor Blockers.
Lu J; Tian Y; Gu J; Qiu M; Lu Y; Sun W; Kong X
J Cardiovasc Pharmacol; 2021 Feb; 77(2):228-237. PubMed ID: 33235029
[TBL] [Abstract][Full Text] [Related]
7. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
8. Impact of calcium channel blockers and angiotensin receptor blockers on hematological parameters in type 2 diabetic patients.
Ahmed GM; Abed MN; Alassaf FA
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1817-1828. PubMed ID: 37750935
[TBL] [Abstract][Full Text] [Related]
9. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Racine N; Hamet P; Sampalis JS; Longo N; Bastien N
J Hum Hypertens; 2010 Nov; 24(11):739-48. PubMed ID: 20147971
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
11. First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care.
Sinnott SJ; Douglas IJ; Smeeth L; Williamson E; Tomlinson LA
BMJ; 2020 Nov; 371():m4080. PubMed ID: 33208355
[TBL] [Abstract][Full Text] [Related]
12. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
Kwok T; Leung J; Barrett-Connor E;
Age Ageing; 2017 Jan; 46(1):57-64. PubMed ID: 28181652
[TBL] [Abstract][Full Text] [Related]
13. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.
Nishida Y; Takahashi Y; Nakayama T; Soma M; Asai S
Cardiovasc Diabetol; 2011 Aug; 10():74. PubMed ID: 21827713
[TBL] [Abstract][Full Text] [Related]
14. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Volpe M; Tocci G
Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
[TBL] [Abstract][Full Text] [Related]
16. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up.
Jeong HS; Lim HS; Park HJ; Lee WS; Choi JO; Lee HS; Jo SH; Hong SJ
Sci Rep; 2021 Jan; 11(1):1783. PubMed ID: 33469103
[TBL] [Abstract][Full Text] [Related]
18. Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis.
Tanaka M; Yamashita T; Koyama M; Moniwa N; Ohno K; Mitsumata K; Itoh T; Furuhashi M; Ohnishi H; Yoshida H; Tsuchihashi K; Miura T;
Clin Exp Nephrol; 2016 Jun; 20(3):469-78. PubMed ID: 26500097
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness.
Andreadis EA; Sfakianakis ME; Tsourous GI; Georgiopoulos DX; Fragouli EG; Katsanou PM; Tavoularis EI; Skarlatou MG; Marakomichelakis GE; Ifanti GK; Diamantopoulos EJ
Int Angiol; 2010 Jun; 29(3):266-72. PubMed ID: 20502415
[TBL] [Abstract][Full Text] [Related]
20. The association of calcium channel blockers with β-cell function in type 2 diabetic patients: A cross-sectional study.
Zhao D; Cao Y; Yu CG; Yuan SS; Zhang N; Zhang YY; Staessen JA; Feng YM
J Clin Hypertens (Greenwich); 2019 May; 21(5):638-647. PubMed ID: 30900372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
